Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LXE408 in Primary Visceral Leishmaniasis
NCT05957978Phase 2Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LXE408 in visceral leishmaniasis (VL), sponsored by Drugs for Neglected Diseases initiative. Started Mar 2024; status: completed.
02
Drugs
LXE408
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT05957978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957978.